The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

Genentech's ranibizumab injection (Susvimo) has received FDA approval for the treatment of diabetic retinopathy. The ...

Researchers said a single daytime sample of serum 17-hydroxyprogesterone and/or androstenedione is sufficient to monitor ...

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

The companion product – Susvimo – is an implantable treatment based on ranibizumab that can extend the time between treatments to six months or more and was approved by the FDA last October.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

In this Healio Video Exclusive, Trevor Angell, MD, speaks with Vivek R. Patel, MD, about how endocrinologists and ophthalmologists can work together when treating thyroid eye disease. The FDA ...

Prostaglandin analogs were associated with a lower risk for uveitis compared with other topical glaucoma medications, according to a retrospective study of more than 64,000 patients published in ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer patients treated with Nubeqa plus ADT experienced a clinically meaningful ...